DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00277-020-03970-2.pdf
Reference49 articles.
1. Ooi MG-M, de Mel S, Chng WJ (2016) Risk stratification in multiple myeloma. Curr Hematol Malig Rep 11:137–147. https://doi.org/10.1007/s11899-016-0307-4
2. Radocha J, Maisnar V, Pour L et al (2016) Multiple myeloma R-ISS prognostic stratification system in real life population. Blood 128:3333 LP–3333333
3. Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, Snir N, Magen H, Koren-Michowitz M, Herzog-Tzarfati K, Keren-Shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-Urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-Miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I (2018) Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med 24:1867–1876. https://doi.org/10.1038/s41591-018-0269-2
4. Walker BA, Boyle EM, Wardell CP et al (2015) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33:3911–3920. https://doi.org/10.1200/JCO.2014.59.1503
5. Hoang PH, Dobbins SE, Cornish AJ, Chubb D, Law PJ, Kaiser M, Houlston RS (2018) Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia. 32:2459–2470. https://doi.org/10.1038/s41375-018-0103-3
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma;Annals of Hematology;2024-09-04
2. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence;British Journal of Haematology;2024-07-19
3. A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies;European Journal of Haematology;2024-07-02
4. Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma;British Journal of Haematology;2023-11-30
5. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study;European Journal of Haematology;2023-11-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3